TriPath identifies biomarkers for cervical cancer screener
This article was originally published in Clinica
Executive Summary
TriPath Imaging has identified a number of biomarkers it believes will help improve the detection of cervical dysplasia and cancer. The company hopes to develop a formulation of the molecular markers for use with its cervical cancer screening test, SurePath. Clinical trials are planned to begin next year.